OCUGEN, INC. Form 8-K (Aug. 25, 2020)

Summary

Current report on Form 8-K of Ocugen, Inc., date of report August 25, 2020, filed under Item 8.01, Other Events. It states that on August 25, 2020 the U.S. Patent and Trademark Office issued a patent titled “Preservative Free Ocular Compositions and Methods for Using the Same for Treating Dry Eye Disease and Other Eye Disorders” to the company. It says the patent relates to OCU300 and OCU310, and that the company has discontinued development of OCU310 and OCU300 and is not currently developing any other therapies related to the patent. The signature block shows /s/ Shankar Musunuri, Chief Executive Officer and Chairman, dated August 31, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

8-K 1 ocgn-20200831x8k.htm 8-K html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

___________________________________________________________

FORM 8–K

___________________________________________________________

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 25, 2020

___________________________________________________________

OCUGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________________________

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

5 Great Valley Parkway, Suite 160

Malvern, Pennsylvania 19355

(484) 328-4701

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

o Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

o Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events

On August 25, 2020, the U.S. Patent and Trademark Office issued U.S. Patent No. 10,751,337 B2, titled “Preservative Free Ocular Compositions and Methods for Using the Same for Treating Dry Eye Disease and Other Eye Disorders” (the “Patent”), to Ocugen, Inc. (the “Company”), which is a continuation-in-part application of U.S. Patent No. 9,597,328, issued March 21, 2017. The Patent relates to OCU300 and OCU310, two product candidates that the Company had previously been developing for the treatment of ocular graft versus-host disease and dry eye disease, respectively. As previously announced in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2020, and in its Current Report on Form 8-K filed with the SEC on June 1, 2020, the Company has discontinued its development of OCU310 and OCU300, and it is not currently developing any other therapies related to the Patent.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 31, 2020

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

2

File and source

File

SEC_OCGN_8-K_filed2020-08-31_0001628280-20-013140.htm

Size

30,014 bytes

SHA-256

9e40e52388c80f92f81947150902d22eb7f27c2be2987edf7106f305a519353f

Our copy

SEC_OCGN_8-K_filed2020-08-31_0001628280-20-013140.htm

Original

www.sec.gov